Table 2. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA.
| Ref | Year | Sex | Clinical status | Organisms detected | Clinical efficacy rate | Microbiologic efficacy rate | Adverse reactions |
|---|---|---|---|---|---|---|---|
| [9] | 1994 | NA | Pneumonia (n = 37) | MRSA (n = 85) | Total 85% | Total 83% | NA |
| Enterocolitis (n = 22) | Pneumonia 84% | Pneumonia 87% | |||||
| UTI (n = 1) | Intra-abdominal infection 79% | Intra-abdominal infection 79% | |||||
| Intra-abdominal infection (n = 14) | UTI 100% | ||||||
| Wound infection (n = 6) | Enterocolitis 82% | ||||||
| Biliary tract infection (n = 5) | Wound infection 100% | ||||||
| Hepatobiliary infection 100% | |||||||
| [10] | 2003 | 29 infants | Sepsis (n = 4) | MRSA (n = 27) | Totalc 79.3% | None | NA |
| Pneumonia (n = 17) | MRCNS (n = 2) | Sepsis 75.0% | |||||
| NEC (n = 3) | Othersb | Pneumonia 82.4% | |||||
| Othersa (n = 4) | Others 75.0% | ||||||
| [11]d | 2008 | M/F; 15/4 | Pneumonia (n = 14) | MRSA (N = 14) | Total 71.4% | Total 46.2% | Subjective symptoms 15.8% |
| Abnormal laboratory finding 36.8% | |||||||
| [31] | 2012 | M/F; 64/39 | SST (n = 66) | MRSA (n = 78) | Total 67.4% | None | NA |
| OM (n = 14) | MRSE (n = 13) | ||||||
| Sepsis (n = 8) | MRSC (n = 4) | ||||||
| Pneumonia (n = 5) | |||||||
| Others (n = 10) | |||||||
| [12] | 2012 | M/F; 10/3 | Sepsis (n = 3) | MRSA | Total 66.7% | Total 62.5% | Total 38.5% |
| Pneumonia (n = 10) | Sepsis 66.7% | Sepsis 50.0% | |||||
| Pneumonia 66.7% | Pneumonia 66.7% | ||||||
| [26] | 2013 | M/F; 16/13 | Sepsis (n = 8) | MRSA (n = 22) | Total 89.7% | MRSA 69.2% | <5 mg/kg; 33.3% |
| Pneumonia (n = 21) | MRSA/PAE (n = 4) | <5 mg/kg; 77.8% | P. aeruginosa 100% | ≥5 to <6; 12.5% | |||
| MRSA/ABA (n = 2) | ≥5 to <6; 87.5% | ≥6; 8.3% | |||||
| MRSA/PAE/ABA (n = 1) | ≥6; 100% |
MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; UTI, urinary tract infection; MRCNS, methicillin-resistant coagulase-negative Staphylococcus species; SST, skin and soft tissue infection; OM, osteomyelitis; MRSE, methicillin-resistant Staphylococcus epidermidis; MRSC, methicillin-resistant Staphylococcus capitis; PAE, Pseudomonas aeruginosa; ABA, Acinetobacter baumannii.
aVentriculitis (n = 1), cellulitis (n = 1), submandibular glanditis (n = 1), funisitis (n = 1), staphylococcal exanthematous disease (n = 1).
b3 coagulase-negative staphylococcus, 2 Enterococcus faecalis, 3 P. aeruginosa, 1 Klebsiella, Enterobacter, Serratia, Acinetobacter.
c6 cases of ABK only, 23 combinations (ampicillin/sulbactam 100% vs. other combination 64.3%, P < 0.05).
dClinical/bacteriologic analysis (n = 14), adverse reactions (n = 19).